Eikon Therapeutics filings document its transition to a Nasdaq-listed public company, its common stock registration, governance documents, financial results, and clinical and corporate updates. The company’s Form 8-K disclosures include results of operations and financial condition, exhibits containing press releases, and amendments to its certificate of incorporation and bylaws in connection with its initial public offering.
The filings also identify Eikon’s common stock, par value, trading symbol, Nasdaq listing, and public-company governance framework. For this clinical-stage biopharmaceutical issuer, regulatory disclosures center on capital structure, shareholder matters, clinical program updates, and corporate reporting obligations.
Eikon Therapeutics reported an ownership disclosure: BlackRock Portfolio Management LLC holds 3,002,737 shares, representing 5.5% of Eikon Therapeutics common stock. The filing lists sole voting power for 2,939,120 shares and sole dispositive power for 3,002,737 shares. The schedule states these holdings reflect certain Reporting Business Units of BlackRock, Inc., and the form is signed by Spencer Fleming on 04/29/2026.
Eikon Therapeutics reported higher operating spending and losses for 2025 but ended the year with a much stronger cash position following its IPO. Research and development expenses rose to $250.3 million in 2025, up 22%, reflecting expanded clinical trial activity and its move into a new Millbrae headquarters.
General and administrative expenses increased to $88.6 million, mainly due to a $21.3 million asset impairment and higher compensation costs. Net loss attributable to common stockholders widened to $333.6 million, or $115.29 per share. Cash, cash equivalents, and marketable securities were $336.0 million at year-end, and a February 2026 upsized IPO raised an additional $381.2 million in gross proceeds, which the company expects will fund operations into the second half of 2027.
Eikon Therapeutics is a late-stage clinical biopharmaceutical company focused on oncology, advancing multiple candidates including EIK1001, EIK1003, EIK1004, EIK1005 and EIK1006. The company reported a 2025 net loss of $324.2 million, driven mainly by research and development spending of $250.3 million and general and administrative costs of $88.6 million.
Cash, cash equivalents and marketable securities totaled $336.0 million at year-end, and a February 2026 IPO added about $349.0 million of net proceeds, which management expects to fund operations into the second half of 2027. Eikon highlights a material weakness in internal control over financial reporting and notes a prior restatement of 2025 interim financials, as well as substantial future funding needs typical for a clinical-stage biotech with an accumulated deficit of $920.5 million.
Eikon Therapeutics, Inc. reported that Chief Operating Officer Michael A. Klobuchar received a grant of stock options for 87,157 shares at an exercise price of $0.00 per share. The award vests in equal monthly installments over 48 months, subject to his continued service.
Huffines Robert Luther reported acquisition or exercise transactions in this Form 4 filing.
Eikon Therapeutics, Inc. reported that director Robert Luther Huffines received a grant of stock options covering 25,873 shares of the company’s stock. These options were awarded as a form of compensation and will vest in equal monthly installments over 48 months, as long as he continues in service during that period.
FRAZIER KENNETH C reported acquisition or exercise transactions in this Form 4 filing.
Eikon Therapeutics director Kenneth C. Frazier reported a new stock option grant covering 25,873 shares of Eikon Therapeutics common stock on March 2, 2026. The option vests in equal monthly installments over 48 months, conditioned on his continued service with the company.
PERLMUTTER ROGER M reported acquisition or exercise transactions in this Form 4 filing.
Eikon Therapeutics director and officer Roger M. Perlmutter received a grant of stock options covering 268,176 shares of the company’s stock. The options were awarded at no cash cost on the grant date. According to the vesting terms, 1/48 of the underlying shares vest monthly over 48 months, contingent on his continued service.
Eikon Therapeutics, Inc. reported that executive Benjamin Bruno Thorner received a grant of stock options covering 67,044 shares of the company’s stock. The options have an exercise price of $0.00 per share and represent a new award rather than an open-market purchase.
According to the vesting terms, one forty-eighth of the option shares will vest on each monthly anniversary of the vesting start date over 48 months, as long as Thorner continues to provide service to the company. This structure ties the award to multi-year retention and ongoing employment.
Eikon Therapeutics Chief Medical Officer Roy D. Baynes reported an option grant giving him rights to acquire 134,088 shares of company stock at an exercise price of $0.00 per share. The option vests in equal monthly installments over 48 months, conditioned on his continued service.
Eikon Therapeutics Chief Financial Officer receives new stock option grant. CFO Alfred Lloyd Bowie Jr. was granted stock options for 67,044 shares of Eikon Therapeutics, Inc. common stock on March 2, 2026, at an exercise price of $0.00 per share, recorded as a grant or award acquisition.
The option vests over four years: 1/48th of the underlying shares vest on each monthly anniversary of the vesting start date for 48 months, provided he continues in service through each vesting date. Following this grant, he directly holds options covering 67,044 shares.